Press Releases

Press Releases

Samsung Biologics presents 2024 business plans at J.P. Morgan Healthcare Conference

[2024%20JPMHC]%20??%20????????%20???%20????%20??%20??%201.jpg

Incheon, S. Korea, January 9, 2024 – Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today presented its 2024 business plans and strategy at the J.P. Morgan Healthcare Conference held in San Francisco, California. 

During the main track presentation, John Rim, CEO and President of Samsung Biologics, announced that the company will continue to add fresh capacity and further diversify its portfolio in the new year to deliver on its commitment to produce high-quality biomedicines and ensure client satisfaction despite a challenging environment.
 

“This year, we expect to face fiercer competition and challenges as we prepare for the next decade of growth,” said Rim. “We will continue to make bold investments in capacity and geographic expansion to address the growing market demand, while securing core capabilities in new modalities to better serve and meet the evolving needs of our clients.”
 

Samsung Biologics broke ground on its second Bio Campus last year and has been accelerating the construction of Plant 5, which will bring up the company’s total biomanufacturing capacity to 784,000 liters upon its completion in April 2025. By 2032, Bio Campus II will house four plants, each with a capacity of 180,000 liters, and combined with Bio Campus I, will enable Samsung Biologics to provide over 1.3 million liters’ capacity to clients worldwide.
 

The company is also building an antibody-drug conjugate (ADC) facility at a separate site, with the aim to commence operations by 2024. The company has been investing in biotech companies with advanced technologies to secure relevant ADC capabilities.
 

Samsung Biologics also plans to expand its partnerships with both global pharma and emerging biotech companies by offering services incorporating its newly launched CDO platforms, S-CHOsientTM and S-GlynTM, that ensure higher productivity and quality of a molecule for successful drug development.
 

In terms of geographical expansion, Samsung Biologics will continue to conduct inorganic expansion studies to identify new sites to work in closer proximity to its clients, in addition to its sales offices in New Jersey and Boston, in the U.S.
 

“Our utmost priority will be providing the highest level of customer-centric services by improving all areas of our business through innovation and technology to bring sustainable value to all of our clients and partners,” added Rim. “We will continue to build on our strong foundation of trust and pursue our mission to deliver high-quality biomedicines to as many patients around the world.”

[2024%20JPMHC]%20??%20????????%20???%20????%20??%20??%201.jpg

Incheon, S. Korea, January 9, 2024 – Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today presented its 2024 business plans and strategy at the J.P. Morgan Healthcare Conference held in San Francisco, California. 

During the main track presentation, John Rim, CEO and President of Samsung Biologics, announced that the company will continue to add fresh capacity and further diversify its portfolio in the new year to deliver on its commitment to produce high-quality biomedicines and ensure client satisfaction despite a challenging environment.
 

“This year, we expect to face fiercer competition and challenges as we prepare for the next decade of growth,” said Rim. “We will continue to make bold investments in capacity and geographic expansion to address the growing market demand, while securing core capabilities in new modalities to better serve and meet the evolving needs of our clients.”
 

Samsung Biologics broke ground on its second Bio Campus last year and has been accelerating the construction of Plant 5, which will bring up the company’s total biomanufacturing capacity to 784,000 liters upon its completion in April 2025. By 2032, Bio Campus II will house four plants, each with a capacity of 180,000 liters, and combined with Bio Campus I, will enable Samsung Biologics to provide over 1.3 million liters’ capacity to clients worldwide.
 

The company is also building an antibody-drug conjugate (ADC) facility at a separate site, with the aim to commence operations by 2024. The company has been investing in biotech companies with advanced technologies to secure relevant ADC capabilities.
 

Samsung Biologics also plans to expand its partnerships with both global pharma and emerging biotech companies by offering services incorporating its newly launched CDO platforms, S-CHOsientTM and S-GlynTM, that ensure higher productivity and quality of a molecule for successful drug development.
 

In terms of geographical expansion, Samsung Biologics will continue to conduct inorganic expansion studies to identify new sites to work in closer proximity to its clients, in addition to its sales offices in New Jersey and Boston, in the U.S.
 

“Our utmost priority will be providing the highest level of customer-centric services by improving all areas of our business through innovation and technology to bring sustainable value to all of our clients and partners,” added Rim. “We will continue to build on our strong foundation of trust and pursue our mission to deliver high-quality biomedicines to as many patients around the world.”

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION